Nbe-therapeutics Ag

The Scripps Research Institute

University of Florida Research Foundation Inc

Lorenz Waldmeier

Ulf Grawunder

Roger Renzo Beerli

Christoph Rader

Haiyong Peng

Ina Hellmann

The present invention relates to fully human antibodies and conjugates thereof, which specifically bind to the extracellular domain of receptor tyrosine kinase-like orphan receptor 2 (ROR2).

Human antibodies binding to ROR2

The present invention relates to a human or humanized antibody, or an antibody-based binding protein, modified antibody format retaining target binding capacity, antibody derivative or fragment retaining target binding capacity, which targets Receptor tyrosine kinase-like orphan receptor-1 (ROR1). It further relates to bi- or multispecific antibodies, to Immunoligand-Drug Conjugates, to Chimeric Antigen Receptors and to T-cells comprising such Chimeric Antigen Receptors.

Anti-ROR1 antibodies

The invention provides antibodies, antibody drug conjugates, antibody-based fragments or antibody fragments (antigen-binding fragments), as well as antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR1 and related compositions. Also provided in the invention are methods of using such antibodies in various diagnostic and therapeutic applications.

ROR1 antibody compositions and related methods

Growing community of inventors

Basel, Switzerland

Lorenz Waldmeier